TNFRSF17 and plasma cell myeloma: In multiple myeloma, Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel), both targeting B-cell maturation antigen (BCMA), have shown promise in treating relapsed or refractory cases, offering new options for patients who have exhausted conventional therapies (40–42).